Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease

被引：14
|
作者：
Roger, Simon D. [1 ]
机构：
[1] Gosford Hosp, Dept Renal Med, Gosford, NSW, Australia
来源：
CLINICAL KIDNEY JOURNAL | 2017年 / 10卷
关键词：
anaemia; CKD; ESRD; ESA; iron; ERYTHROPOIESIS-STIMULATING AGENTS; RANDOMIZED CONTROLLED-TRIAL; CHRONIC-RENAL-FAILURE; INTRAVENOUS IRON; ORAL IRON; HEMODIALYSIS-PATIENTS; DEFICIENCY ANEMIA; IV IRON; SERUM FERRITIN; SUCROSE;
D O I：
10.1093/ckj/sfx100
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Clinical practice guidelines provide both local and global recommendations for the use of iron therapy in the management of anaemia in patients with chronic kidney disease. However, physicians must interpret and adapt these guidelines to meet the specific needs of their individual patients. The recommendations must also be considered in the context of findings from more recently published clinical trials and observational studies.
引用
收藏
页码：9 / 15
页数：7
相关论文
共 50 条
  • [1] Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions
    Macdougall, Iain C.
    CLINICAL KIDNEY JOURNAL, 2017, 10 : 16 - 24
  • [2] Iron therapy for managing anaemia in chronic kidney disease
    Macdougall, Iain C.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2018, 27 (05) : 358 - 363
  • [3] Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients
    Malyszko, Jolanta
    Anker, Stefan D.
    CLINICAL KIDNEY JOURNAL, 2017, 10 : 25 - 31
  • [4] Heme iron polypeptide for the management of anaemia of chronic kidney disease
    Dull, R. B.
    Davis, E.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (04) : 386 - 390
  • [5] Iron Localization and Infectious Disease in Chronic Kidney Disease Patients
    Nakanishi, Takeshi
    Kuragano, Takahiro
    Nanami, Masayoshi
    Hasuike, Yukiko
    AMERICAN JOURNAL OF NEPHROLOGY, 2016, 43 (04) : 237 - 244
  • [6] Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
    Macdougall, Iain C.
    Bircher, Andreas J.
    Eckardt, Kai-Uwe
    Obrador, Gregorio T.
    Pollock, Carol A.
    Stenvinkel, Peter
    Swinkels, Dorine W.
    Wanner, Christoph
    Weiss, Guenter
    Chertow, Glenn M.
    KIDNEY INTERNATIONAL, 2016, 89 (01) : 28 - 39
  • [7] A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients
    Qunibi, Wajeh Y.
    Martinez, Carlos
    Smith, Mark
    Benjamin, Joseph
    Mangione, Antoinette
    Roger, Simon D.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (05) : 1599 - 1607
  • [8] Interpretation of the Kidney Disease: Improving Global Outcomes guidelines for iron therapy: commentary and emerging evidence
    Berns, Jeffrey S.
    CLINICAL KIDNEY JOURNAL, 2017, 10 : 3 - 8
  • [9] Iron metabolism and management: focus on chronic kidney disease
    Agarwal, Anil K.
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2021, 11 (01) : 46 - 58
  • [10] Efficacy of IV Iron Compared to Oral Iron for Increment of Haemoglobin Level in Anemic Chronic Kidney Disease Patients on Erythropoietin Therapy
    Adhikary, L.
    Acharya, S.
    JOURNAL OF NEPAL MEDICAL ASSOCIATION, 2011, 51 (03) : 133 - 136
12345